The impact of menstrual disorders on quality of life in women with inherited bleeding disorders
R. A. KADIR
Haemophilia Centre and Haemostasis Unit, Department of Obstetrics and Gynaecology, Royal Free Hospital, London, UK
Search for more papers by this authorM. EDLUND
Department of Obstetrics and Gynaecology, Danderyds Hospital, Stockholm, Sweden
Search for more papers by this authorS. VON MACKENSEN
Institute of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Search for more papers by this authorR. A. KADIR
Haemophilia Centre and Haemostasis Unit, Department of Obstetrics and Gynaecology, Royal Free Hospital, London, UK
Search for more papers by this authorM. EDLUND
Department of Obstetrics and Gynaecology, Danderyds Hospital, Stockholm, Sweden
Search for more papers by this authorS. VON MACKENSEN
Institute of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Search for more papers by this authorAbstract
Summary. Menorrhagia, heavy menstrual bleeding, is a common condition that has a substantial impact on the lives of many women. The objective measurement of menorrhagia is often impractical; therefore diagnosis and treatment are usually based on the direct perception of the woman. Menstrual problems are likely to be worse in women with bleeding disorders, as they are more likely to have heavy and painful menstrual periods and ovulation bleeding and pain. These can have a major impact on the quality of women's lives, especially those who suffer heavy menstruation. These problems can also lead to limitations at work and school and hinder educational and academic achievements. Only few studies describe how quality of life (QOL) changes in women with an underlying haemostatic defect; poorer QOL being associated with more frequent bleeding symptoms. Early recognition, accurate diagnosis and appropriate management of bleeding disorders should improve not only the quality of care for affected women but also their QOL. Increased awareness of the high prevalence of menstrual problems especially menorrhagia is essential for early diagnosis and provision of appropriate treatments without any delay. Accurate knowledge of the impact of menorrhagia on health-related quality of life (HRQOL) and its adequate assessment help individualize treatment and assess the magnitude of changes in HRQOL. An ideal situation would be to use a generic and a disease-specific measure together so that comparisons can be made on a general and disease-specific level.
References
- 1 Kouides PA, Phatak PD, Burkart P et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia 2000; 6: 643–8.
- 2 Kadir RA, Sabin CA, Pollard D, Lee CA, Economides DL. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia 1998; 4: 836–41.
- 3 Kouides P, Phatak PD, Braggins C et al. Gynaecological and obstetrical morbidity in women with type 1 von Willebrand disease: results of a petient survey. Haemophilia 2001; 6: 643–8.
- 4 Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2001; 99: 238–43.
- 5 Clark TJ, Khan KS, Foon R, Pattison H, Bryan S, Gupta JK. Quality of life instruments in studies of menorrhagia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 104: 96–104.
- 6 Kulkarni A, Lee CA, Griffeon A, Kadir RA. Disorders of menstruation and their effect on the quality of life in women with congenital factor VII deficiency. Haemophilia 2006; 12: 248–52.
- 7 Van Eijkeren MA, Christiaens GH, Scholten PC, Sixma JJ. Menorrhagia. Current drug treatment concepts. Drugs 1992; 43: 201–9.
- 8 Edlund M, Magnusson C, Von Schoultz B. Quality of Life – A Swedish Survey of 2200 Women. London: The Royal Society of Medicine Press Limited, London; 1994: p. 36–7.
- 9 Liu Z, Doan QV, Blumenthal P, Dubbois RW. A systematic review evaluating health-related quality of life, work impairement, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007; 10: 183–94.
- 10 Thompson BL, Ponce de Leon R, Kieke B, Velebil P, Wingo PA. Trends in hospitalizations for abnormal uterine bleeding in the United states: 1980–1992. J Womens Health 1997; 6: 73–81.
- 11 Kadir RA, Economides DL, Sabin CA, Pollard D, Lee CA. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia 1999; 5: 40 –8.
- 12 Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 485–9.
- 13 Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. Haemophilia 1999; 5: 313–7.
- 14 Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 784–90.
- 15 Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH et al. Bleeding in carriers of hemophilia. Blood 2006; 108: 52–6.
- 16 Lukes AS, Kadir RA, Peyvandi F, Kouides PA. Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. Fertil Steril 2005; 84: 1338–44.
- 17 Smith YR, Quint EH, Hertzberg RB. Menorrhagia in adolescents requiring hospitalization. J Pediatr Adolesc Gynecol 1998; 11: 13–5.
- 18 Claessens EA, Cowell CA. Acute adolescent menorrhagia. Am J Obstet Gynecol 1981; 139: 277–80.
- 19 Friberg B, Orno A, Lindgren A, Lethagen S. Bleeding disorders amoung young women: a population-based prevelence study. Obstet Gynecol Scand 2006; 85: 200–6.
- 20 Chi C, Pollard D, Tuddenham EG, Kadir RA. Menorrhagia in adolescents with inherited bleeding disorders. J Pediatr Adolesc Gynecol 2010; [Epub ahead of print].
- 21 Silwer J. von Willebrand’s disease in Sweden. Acta Paediatr Scand Suppl 1973; 238: 1–159.
- 22 Anastasakis E, Kingman CE, Lee CA, Economides DL, Kadir RA. Menstrual problems in university students: an electronic mail survey. In Vivo 2008; 22: 617–20.
- 23 Pawar A, Krishnan R, Davis K, Bomas K, Kulkarni R. Perceptions about quality of life in a school-based population of adolescents with menorrhagia: implications for adolecents with bleeding disorders. Haemophilia 2008; 14: 579–83.
- 24 Jenkinson C, Peto V, Coulter A. measuring changes over time: a comparison of results from a global single item of health status and the multi-dimensional SF36 health status survey questionnaire in pateints presenting with menorrhagia. Qual Life Res 1994; 3: 317–21.
- 25 Garratt AM, Ruta DA, Abdalla M, Buckingham J, Russell I. The SF-36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993; 29: 1440–4.
- 26 Angela C, Peto V, Jenkinson C. Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract 1994; 11: 394–400.
- 27 Cooper K, Bain C, Parkin D. Comparision of microwave endometrial ablation and transcervial resection of the endometrium for treatment of heavy menstrual loss. Lancet 1999; 345: 1859–63.
- 28 Cooper K, Jack S, Parkin D, Grant A. Five year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. Br J Obstet Gynaecol 2001; 108: 1222–8.
- 29 Hurskainen R, Teperi J, Rissanen P et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357: 273–7.
- 30 Duleba A, Heppard M, Soderdtrom R, Townsend D. A randomised study coomparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. J Am Assoc Gynecol Laparosc 2003; 10: 17–26.
- 31 Abbott J, Hawe J, Hunter D, Garry R. A double blind randomized trial comparing the Cavaterm and the NovaSure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertil Steril 2003; 80: 203–8.
- 32 Hawe J, Abbott J, Hunter D, Phillips G, Garry R. A randomised control trial comparing the Cavaterm endometrial ablation system with the Nd:YAG laser for the treatment of dysfunctional uterine bleeding. BJOG 2003; 110: 350–7.
- 33 Abbott J, Hawe J, Garry R. Quality of life should be considered the primary outcome for measuring success of endometrial ablation. J Am Assoc Gynecol Laparosc 2003; 10: 491–5.
- 34 Shankar M, Chi C, Kadir RA. Review of quality of life: menorrhagia in women with or without inherited bleeding disorders. Haemophilia 2008; 14: 15–20.
- 35 Jenkinson C, Coulter A, Wright L. Short form 36 (SF-36) health survey questionnaire: normative data for adults of working age. BMJ 1993; 306: 1437–40.
- 36 McHorney C, Ware J, Raczek A. The MOS 36-Item Short-Form Health Survey (SF-36): II. psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247–63.
- 37 Solovieva S. Clinical severity of disease, functional disability and health-related quality of life. Three year follow-up study of 150 Finnish patients with coagulation disorders. Haemophilia 2001; 7: 53–63.
- 38 Barr RD, Sek J, Horsman J et al. Health status and health-related quality of life associated with von Willebrand disease. Am J Hematol 2003; 73: 108–14.
- 39 Rozeik C, Scharrer I. Defekt des von Willebrand Faktor-proteins. Gynakologische und psychische Probleme bei Frauen mit von Willebrand-Syndrom. Gynakologische Geburtshilfe 2001; 3: 70–5.
- 40 Wittchen H-U, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 355–64.
- 41 Shapiro D, Donfield S, Lynn H. Defining the impact of hemophillia: the academic achievement in children with hemophillia study. Pediatrics 2001; 108: E105.
- 42 Halterman JS, Kaczorowski JM, Aligne CA, Auinger P, Szilagyi PG. Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States. Pediatrics 2001; 107: 1381–6.
- 43 Bruner AB, Joffe A, Duggan AK, Casella IF, Brandt JT. Randomized study of cognitive effects of iron supplementations in non-anemic iron-deficient adolescent girls. Lancet 1996; 348: 992–6.
- 44 Patterson AJ, Brown WJ, Roberts DCK. Dietary and supplementation treatment of iron deficiency results in improvements in general health and fatigue in Australian wome of childbearing age. J Am Coll Nutr 2001; 20: 337–42.
- 45 Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 734–9.
- 46 Naftalin J, Kadir R. Life-threatening menorrhagia secondary to Factor VII deficiency and leiomyomata. J Obstet Gynaecol 2006; 26: 479–80.
- 47 Kadir RA. Menorrhagia:treatment options. Thromb Res 2009; 123 Suppl. 2: S21–S29.
- 48 James AH, Kouides P, Kadir RA et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009; 201: 12.e1–8 (Epub 2009).
- 49 Lee CA, Chi C, Pavord SR et al. The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization. Haemophilia 2006; 12: 301–36.
- 50 Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004; 111: 1425–8.
- 51 Chi C, Chase A, Kadir RA. Levonorgestrel-releasing intrauterine systemfor the management of menorrhagia in women with bleeding disorders: long-term follow-up. Contraception 2010 (in press).
- 52 Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16 Suppl. 1; S23–S26.
- 53 Ruta DA, Garratt AM, Chadha YC, Flett GM, Hall MH, Russell IT. Assessment of patients with menorrhagia: how valid is a structured clinical history as a measure of health status? Qual Life Res 1995; 4: 33–40.
- 54 Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145: 212–20.
- 55 Von Mackensen S, Federici A. Quality of life assessment in patients with von Willebrand’s disease: development of a first disease-specific instrument (VWD-QoL). Hamostaseologie 2007; 1: 126.